Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China
|
MSCI China Small-Cap
|
Hang Seng Index
|
Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Cloudbreak Pharma

Hong Kong’s tighter IPO scrutiny may delay deals but could strengthen investor trust over time

Hong Kong tightens listing oversight to build lasting trust

Tighter IPO scrutiny by the city’s securities regulators may delay deals but could strengthen investor trust over the longer term    By Lee Shih Ta “A market can be competitive…
October 29, 2026
Cloudbreak Pharma shares halted amid probe into “IPO rigging”

Cloudbreak Pharma shares halted amid probe into ‘IPO rigging’

Just 14 months after its market debut, the drug developer is under investigation over regulatory concerns that its IPO demand was artificially inflated Key Takeaways: Cloudbreak’s IPO drew strong retail…
September 17, 2026
2592.HK
VivaVision IPO

Eye drug maker VivaVision feels the strain in IPO funding dash

The developer of new treatments for ocular disorders is in a race against time to secure a Hong Kong listing before its cash reserves run out Key Takeaways: Two VivaVision…
February 26, 2026
Cloudbreak Pharma IPO

Cloudbreak Pharma sets sights on Hong Kong IPO after license deal

The developer of eye drugs has yet to launch a product on the market and could face financial pressure if its latest listing attempt falters Key Takeaways: Cloudbreak has sold…
December 12, 2024

Recent Articles

Hong Kong’s tighter IPO scrutiny may delay deals but could strengthen investor trust over time
October 29, 2026

Hong Kong tightens listing oversight to build lasting trust

September 17, 2026

Cloudbreak Pharma shares halted amid probe into ‘IPO rigging’

2592.HK
February 26, 2026

Eye drug maker VivaVision feels the strain in IPO funding dash

December 12, 2024

Cloudbreak Pharma sets sights on Hong Kong IPO after license deal

RELATED ARTICLES

  1. Tinci IPO gets CSRC approval
    September 17, 2026
    Is Tinci Materials limping to a Hong Kong IPO?
    002709.SHE
  2. June 10, 2026
    Unsated by Hong Kong listing, Knowledge Atlas seeks more funds in Shanghai
    2513.HK
  3. July 30, 2026
    Why Hong Kong-listed companies are switching from IFRS to China accounting
  4. September 17, 2026
    Cloudbreak Pharma shares halted amid probe into ‘IPO rigging’
    2592.HK
  5. October 7, 2026
    Hong Kong securities industry posts $6.58 billion first-half profit on record transactions
  6. September 9, 2026
    Moonshot aims for meteoric valuation with a $3 billion Hong Kong IPO plan
  7. September 23, 2026
    What an AI breach of WeChat and Jollibee’s listing choice mean for U.S.-Asia tech and capital
    0700.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2026 Bamboo Works. All rights reserved.